NFL Biosciences Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	-	1.91	2.34	3.04	0.31
Short-Term Investments	-	0.2	0.19	0.17	-
Cash & Short-Term Investments	-	2.11	2.53	3.2	0.31
Cash Growth	-	-16.45%	-21.07%	933.15%	-
Other Receivables	-	1.06	1.11	0.22	0.16
Receivables	-	1.06	1.11	0.22	0.16
Prepaid Expenses	-	0.17	0.18	0.13	-
Total Current Assets	-	3.34	3.82	3.56	0.47
Property, Plant & Equipment	-	0.12	0.01	0	-
Long-Term Investments	-	-	-	0	-
Other Intangible Assets	-	0.15	0.14	0.12	0.11
Other Long-Term Assets	-	-0	0	-	-
Total Assets	-	3.61	3.97	3.69	0.58
Accounts Payable	-	1.15	2.16	0.12	0.05
Accrued Expenses	-	0.25	-	0.07	-
Short-Term Debt	-	-	-	0	-
Current Portion of Long-Term Debt	-	0.02	-	-	-
Current Income Taxes Payable	-	-	0.2	-	0.04
Other Current Liabilities	-	-	-	-	0
Total Current Liabilities	-	1.42	2.37	0.19	0.09
Long-Term Debt	-	0.02	0.06	0.09	0.09
Other Long-Term Liabilities	-	1.19	1.19	0.13	0.25
Total Liabilities	-	2.63	3.62	0.4	0.43
Common Stock	-	0.29	0.24	0.16	0.39
Additional Paid-In Capital	-	2.76	7.27	4.11	1.85
Retained Earnings	-	-2.08	-7.17	-0.98	-2.09
Comprehensive Income & Other	-	0	-	-	-
Shareholders' Equity	-	0.98	0.35	3.29	0.15
Total Liabilities & Equity	-	3.61	3.97	3.69	0.58
Total Debt	-	0.04	0.06	0.09	0.09
Net Cash (Debt)	-	2.07	2.47	3.12	0.23
Net Cash Growth	-	-16.00%	-20.92%	1285.36%	-
Net Cash Per Share	-	0.21	0.30	0.60	-
Filing Date Shares Outstanding	-	9.83	8.16	5.23	-
Total Common Shares Outstanding	-	9.83	8.16	5.23	-
Working Capital	-	1.92	1.45	3.37	0.38
Book Value Per Share	-	0.10	0.04	0.63	-
Tangible Book Value	-	0.83	0.21	3.16	0.04
Tangible Book Value Per Share	-	0.08	0.03	0.60	-
Machinery	-	0.18	0.05	0.04	0.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.